Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mivavotinib · TAK-659, CB-659

Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Calithera Biosciences

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Mivavotinib?

Mivavotinib is an inhibitor of spleen tyrosine kinase (SYK), a B-cell receptor-associated kinase. By blocking SYK, it inhibits downstream B-cell receptor signaling, B-cell activation, and proliferation. It is studied in non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TAK-659, CB-659, TAK-659F
Drug type
Small molecule
Targets
spleen tyrosine kinase (SYK)
Mechanism
Inhibitor of spleen tyrosine kinase (SYK)
Pathways
B-cell receptor signaling, B-cell activation, chemotaxis, adhesion and proliferation
Therapy area
Oncology
Developer
Calithera Biosciences, Inc
In trials of
NKTR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
8QR88H79VX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03772288 Phase 1 Lymphoma, Non-Hodgkin Withdrawn NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lymphoma, Non-Hodgkin

Other drugs acting on SYK

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.